Published 2021 | Version v1
Journal article

Why did European Radiology reject my radiomic biomarker paper? How to correctly evaluate imaging biomarkers in a clinical setting

  • 1. Centre for Medical Imaging, University College London UCL, 43-45 Foley Street, W1W 7TS, London (United Kingdom)
  • 2. Department of Diagnostic and Interventional Radiology, Saint Antoine Hospital, APHP-Sorbonne University, Paris (France)

Description

This review explains in simple terms, accessible to the non-statistician, general principles regarding the correct research methods to develop and then evaluate imaging biomarkers in a clinical setting, including radiomic biomarkers. The distinction between diagnostic and prognostic biomarkers is made and emphasis placed on the need to assess clinical utility within the context of a multivariable model. Such models should not be restricted to imaging biomarkers and must include relevant disease and patient characteristics likely to be clinically useful. Biomarker utility is based on whether its addition to the basic clinical model improves diagnosis or prediction. Approaches to both model development and evaluation are explained and the need for adequate amounts of representative data stressed so as to avoid underpowering and overfitting. Advice is provided regarding how to report the research correctly.

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00330-021-07971-1

Additional details

Identifiers

Publishing Information

Journal Title
European Radiology (Internet)
Journal Volume
31
Journal Issue
12
Journal Page Range
p. 9361-9368
ISSN
1432-1084
CODEN
EURAE3